PTC's Votoplam Shows Long-Term Promise in Huntington’s Disease Study
Event summary
- PTC Therapeutics will report 24-month interim results from the PIVOT-HD long-term extension study of votoplam on April 28, 2026.
- Novartis, PTC’s partner, stated that the data supports its ongoing Phase 3 INVEST-HD trial.
- Votoplam is a small molecule splicing modifier targeting Huntingtin (HTT) protein reduction in Huntington’s disease.
- The study included both Stage 2 and Stage 3 patients, with primary endpoints focused on blood HTT lowering and safety.
The big picture
PTC’s votoplam represents a novel approach to Huntington’s disease, leveraging its splicing platform technology. The long-term extension data could validate Novartis’ Phase 3 strategy, positioning the program as a potential first-in-class therapy in a market with no approved disease-modifying treatments. The collaboration with Novartis underscores the strategic importance of this asset in PTC’s pipeline.
What we're watching
- Regulatory Pathway
- Whether the FDA will engage on potential accelerated approval based on these long-term data.
- Novartis Collaboration
- How Novartis and PTC will align on next steps for votoplam’s development and commercialization.
- Clinical Efficacy
- The extent to which the 24-month data demonstrate sustained HTT lowering and clinical benefit in Huntington’s patients.
Related topics